Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 105.55M | 119.91M | 166.66M | 156.24M | 147.79M | 130.46M |
Gross Profit | 66.05M | 76.00M | 103.09M | 93.58M | 82.94M | 69.03M |
EBITDA | 633.00K | 3.02M | -11.23M | -4.91M | 2.62M | -12.83M |
Net Income | -56.74M | -56.38M | -82.67M | -14.86M | 4.13M | -23.98M |
Balance Sheet | ||||||
Total Assets | 190.60M | 202.74M | 270.63M | 349.13M | 347.54M | 365.61M |
Cash, Cash Equivalents and Short-Term Investments | 53.37M | 55.63M | 72.87M | 86.33M | 94.39M | 98.32M |
Total Debt | 25.44M | 25.93M | 29.04M | 30.89M | 19.24M | 20.88M |
Total Liabilities | 42.21M | 48.75M | 58.37M | 63.56M | 60.45M | 93.20M |
Stockholders Equity | 148.40M | 153.99M | 212.26M | 285.56M | 287.08M | 272.40M |
Cash Flow | ||||||
Free Cash Flow | -3.35M | -2.33M | -7.21M | -3.08M | 3.25M | 11.44M |
Operating Cash Flow | 5.40M | 5.40M | -1.79M | 4.41M | 8.40M | 13.06M |
Investing Cash Flow | -4.85M | -8.33M | -5.43M | -7.49M | -3.12M | -71.26M |
Financing Cash Flow | -15.89M | -12.73M | -6.32M | -4.85M | -6.78M | -3.77M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
70 Outperform | $156.07M | 23.10 | 16.56% | ― | 14.85% | 64.96% | |
55 Neutral | $141.69M | ― | -407.50% | ― | 32.24% | -66.93% | |
51 Neutral | $7.39B | 0.36 | -62.86% | 2.37% | 15.48% | -2.68% | |
51 Neutral | $249.59M | ― | -87.65% | ― | 2.47% | 56.93% | |
47 Neutral | $159.88M | ― | 271.41% | ― | 85.03% | 53.73% | |
45 Neutral | $66.82M | ― | -66.88% | ― | 18.24% | 4.81% | |
44 Neutral | $120.39M | ― | -22.91% | ― | -25.85% | 18.18% |
On July 30, 2025, Anika Therapeutics announced the topline results from its U.S. pivotal FastTRACK Phase III study for Hyalofast, a cartilage repair scaffold. While the study showed consistent improvements in pain and function measures, it did not meet its pre-specified co-primary endpoints due to factors such as a higher dropout rate and missed visits during COVID. Despite this, Hyalofast demonstrated statistically significant improvements in secondary endpoints, supporting its favorable safety and effectiveness profile. Anika plans to file the final PMA module by the end of 2025, seeking FDA approval under the Breakthrough Device Designation.
The most recent analyst rating on (ANIK) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Anika Therapeutics stock, see the ANIK Stock Forecast page.
On June 20, 2025, Anika Therapeutics held its Annual Meeting of Stockholders where several key proposals were approved. The stockholders elected three directors to serve until 2028, ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for 2025, approved executive compensation, and endorsed an amendment to the 2017 Omnibus Incentive Plan. These decisions are expected to influence the company’s strategic direction and governance structure, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (ANIK) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Anika Therapeutics stock, see the ANIK Stock Forecast page.